Chris joins NeoGenomics from OrthoClinical Diagnostics where he served as Chairman and CEO from 2019 to May of 2022. During his leadership, OrthoClinical raised $1.45 billion in funding in a Q1 2021 initial public offering and achieved accelerated revenue growth from 1% annually to low double-digit levels while simultaneously improving profitability. Chris also successfully guided the company through a combination with Quidel that closed in May 2022.
Prior to OrthoClinical, Chris served in key executive leadership positions at Cochlear Limited, a global market leader in implantable hearing solutions with over $1.2 billion in annual revenue. Having initially joined Cochlear as President of Cochlear Americas in 2004, Chris helped grow division revenue from $80 million to over $400 million before being named CEO in 2015. During his tenure as CEO from 2015 to 2018, Chris oversaw a 35% organic improvement in annual revenues and improved profitability.
Bill Bonello is NeoGenomics’ Chief Financial Officer, where his extensive capital markets and financial analysis background is invaluable to our growth strategy. Mr. Bonello, who joined NeoGenomics in 2017, has served as President of the Informatics division, Chief Strategy and Corporate Development Officer and Director of Investor Relations.
Prior to joining NeoGenomics, Bill worked as a healthcare equity analyst covering diagnostic services and product stocks at various investment banks, including Piper Jaffray, Wachovia Securities, RBC Capital Markets and Craig-Hallum Capital Group. Bill also served as Senior Vice President for Investor Relations at LabCorp. Mr. Bonello received his B.A. degree from Carleton College and his MBA from the Kellogg School of Management at Northwestern University.
David Sholehvar President, Clinical Services Division
Dr. Sholehvar most recently served as Chief Executive Officer at Dynex Technologies, INC. He has experience successfully managing large commercial organizations and driving revenue above market growth where he has shown an ability to lead change and scale businesses through discipline and process innovation.
Dr. Sholehvar started his business career as an entrepreneur co-founding an imaging company that would serve as a predecessor for what has become a robust digital pathology market. He has over 20 years of general management and senior commercial experience in diagnostics and medical devices including roles at Johnson and Johnson, Quest Diagnostics, and as CEO of a global diagnostic instrumentation company.
David has had numerous strategic roles, responsible for identifying white space to create and invest in new products and markets within the IVD and lab services markets. Including being part of the team that launched the first FDA approved, liquid biopsy assay based on circulating tumor cells.
President of Lab Operations and Chief Scientific Officer
Shashikant Kulkarni President of Lab Operations and Chief Scientific Officer
Dr. Kulkarni most recently served as Chief Scientific Officer and Senior Vice President of Innovation and Emerging Business at Baylor Genetics. At Baylor, he led an extensive clinical and translational research team, delivering top-quality clinical genomics and multi-omics tools.
Dr. Kulkarni is considered a world-renowned expert and key opinion leader in cancer genomics with a focus on applying genomic and multi-omic technologies to improve the understanding of human disease and the precision of clinical diagnosis, prognosis, and treatment. He has given numerous national and international presentations and, as a leading voice, presented his insight, thoughts, and opinions as a frequent guest on multiple major news outlets across the country. Additionally, he has published extensively in peer-reviewed articles and numerous well-known journals. He is the Editor-in-Chief of Cancer Genetics Journal and has co-edited a book, available on Amazon, titled Clinical Genomics – A Guide to Clinical Next-Generation Sequencing.
Vishal Sikri President and Chief Commercial Officer of Inivata
Vishal Sikri has over 20 years of experience in the somatic diagnostics space and most recently was President of Oncology at Invitae. Prior to Invitae, Vishal served as U.S. General Manager for Biocartis leading all commercial operations. He has extensive precision medicine experience, having launched and commercialized tests for therapy selection and molecular residual disease in the U.S. and globally across different molecular platforms. Vishal brings years of proven success as a dynamic leader in large organizations. He holds degrees in Molecular Biology and Pharmaceutical Sciences from UW-Madison and an MBA from Loyola University.
Kathryn B. McKenzie Chief Sustainability and Risk Officer
Kathryn McKenzie serves as Chief Sustainability and Risk Officer for NeoGenomics. In this role, she oversees our environmental, social and governance initiatives as well as our risk management activities.
She joined NeoGenomics in 2017 as our Chief Accounting Officer and Vice President of Finance and was most recently our Chief Financial Officer through December 2021. Prior to joining NeoGenomics, Ms. McKenzie served in various roles at Chico’s FAS, including as Assistant Controller and had responsibilities for SEC reporting, accounting, cash management and treasury. Ms. McKenzie began her career at Ernst and Young in assurance, primarily serving financial institutions and healthcare clients. Ms. McKenzie is a Certified Public Accountant and holds a Master's of Science in Accountancy from the University of North Carolina Wilmington.
John Mooney was named NeoGenomics’ Chief Technology Officer in 2021.
Prior to joining the company, John held several roles of increasing responsibility at BioReference Laboratories and served as their Chief Information Officer from 2016 – 2021. During his tenure at BioReference, the company revenues grew from $422M to greater than $1.4B.
Earlier in his career, John worked for several software companies and was the founding architect for two successful digital health startups. He is a subject matter expert in healthcare interoperability, having shaped standards for HL7 and ONC.
John holds a B.S. in Operations & Information Management from the University of Scranton.
Mr. Silva has over 17 years of sales, marketing and general management experience in healthcare delivery, medical devices and diagnostics, and pharmaceuticals. Mr. Silva joined NeoGenomics in June 2020 as the Chief Marketing Officer, after leading Precision Medicine efforts at Novartis resulting in the the successful 2019 launch of PIQRAY (alpelisib) and 2020 launch of TABRECTA (capmatinib).
Prior to Novartis, Mr. Silva was with Becton Dickinson (BD) where he first led global strategic marketing excellence for their $1B global injection business and later was appointed head of Marketing and Analytics for their $700M US Diabetes Care business. Prior to BD, Mr. Silva was with Johnson & Johnson’s Ortho-Clinical Diagnostics franchise, where he held various leadership roles within Global Marketing, Strategic Marketing and Regional Marketing, including multiple product and campaign launches. Prior to this, Mr. Silva started his own healthcare company based in Southern California that focused on senior care, which he ran for almost 10 years and grew to over 100 employees. Additionally, Mr. Silva began his career as a practicing California plaintiff’s attorney, litigating employment law cases in Southern California.
Mr. Silva earned his BA from Rutgers University, his JD from California Western School of Law, and his MBA from Rutgers Business School, with a focus on Marketing and Pharmaceutical Management.
Hutan most recently served as Chief Compliance Officer at Progenity, Inc., a women's health diagnostics company. A strategic and tactical executive, he counseled all levels of the organization, including the Board of Directors and executive management, on legal, compliance, and privacy issues facing the life sciences and biotech industry. Before joining Progenity in 2019, Mr. Hashemi was the Chief Compliance Officer at Genoptix, Inc., before the merger with NeoGenomics in 2018. Earlier in Hutan's legal career, he worked in private practice at law firms advising real estate and financial clients on a wide range of commercial, regulatory, corporate, litigation, and intellectual property matters.
Hutan's experience and background accentuate our unwavering commitment to achieving high compliance standards across our organization.
Ali Olivio General Counsel and Corporate Secretary
Ali has been serving as Interim General Counsel since mid-April 2022.
Ms. Olivo has more than 14 years of corporate and legal expertise. She has been with NeoGenomics for nearly three years representing NeoGenomics in its acquisition of Inivata and Trapelo, as well as fundraising and governance activities. At Neo, she has also represented the company in various regulatory matters, including before CAP, OCR, and the OIG.
Prior to joining NeoGenomics, Ms. Olivo served as a Director at PricewaterhouseCoopers, LLP, negotiating incentives for numerous Fortune 500 clients. Ms. Olivo also spent many years at General Electric in various roles, increasing scope and responsibility, including Counsel, where she oversaw incentives negotiations, tax controversy, and government affairs
Steven G. Brodie, Ph.D. Senior Vice President, Laboratory Operations
Dr. Brodie is the Vice President of Worldwide Pharma Services Operations at NeoGenomics Laboratories. He is also the Laboratory Director for NeoGenomics Europe S.A. Previously he served as the company’s President of the Pharma Services division, Chief Scientific Officer, Director of BioPharma Operations, Laboratory Director, and Director of Molecular and Cytogenetics. Prior to joining NeoGenomics in 2011, Dr. Brodie served as Senior Director of Cytogenetics, Assistant Director of Molecular Genetics, and Scientific Director of Maternal Serum Screening at Specialty Laboratories/Quest Diagnostics in Valencia, CA. Dr. Brodie trained pathology residents in genetic testing at both Loma Linda University Medical Center, where he served as the Affiliate Rotation Director, and University of Southern California, Keck School of Medicine, where he served as a Clinical Assistant Professor of Pathology. Prior to joining Quest Diagnostics, he held a variety of research and clinical positions at the National Institutes of Health, University of New Mexico School of Medicine, and UCLA David Geffen School of Medicine. Dr. Brodie received his genetics training at the UCLA/Cedar-Sinai Medical Center medical genetics training program in Los Angeles, CA. He received his PhD from UNM School of Medicine and completed Clinical Genetics training in Cytogenetics and Molecular Genetics at UCLA. Dr. Brodie is Board Certified by the American Board of Medical Genetics in these specialties and holds Director’s licenses in Florida, California, and New York. Throughout his career, Dr. Brodie has held various research and clinical positions at the NIH, UNM and UCLA, and comes to us after directing high throughput testing in Cytogenetics, FISH, Molecular Genetics, and Oncology for Quest Diagnostics, Nichols Institute. He is also a CAP approved Inspector.